Edward J Stepanski discusses the underlying tension between payers and providers with respect to the aims of clinical pathways and the recent policy statement released by the American Society of Clinical Oncology.
The essential role of patient navigation and care coordination services in helping patients to adhere to their treatment plans.
The authors discuss tactics for ensuring appropriate compliance with clinical pathways among health care providers in large-scale health networks.
This article provides a comprehensive review of psoriasis and of the practical obstacles encountered in optimizing care of patients with moderate-to-severe disease.
A Clinical Pathway to Reduce Time to Antibiotic Administration in Pediatric Cancer Patients With Fever and Potential Neutropenia
The authors present a novel clinical pathway for treating febrile pediatric patients on chemotherapy or recently post–stem cell transplant.
Before the relative value of a drug can be determined, one must first consider how value is defined by the patient. Dr. Benson and Ms. McClure respond to a viewpoint by Roger Longman, MA.
Roger Longman, MA, offers a perspective on how we can overcome comparative effectiveness research and bring a greater understanding on which drugs work best.
The Use of Risk-Sharing Agreements to Manage Costs, Mitigate Risk, and Improve Value for Pharmaceutical Products
The authors review the types of risk-sharing agreements that have been implemented to date.
Clinical pathways are intended to be used by a multidisciplinary health care team in order to achieve the Triple Aim of healthcare reform.
The Use of Incremental Cost-Effectiveness Ratio Thresholds in Health Technology Assessment Decisions
Cost-effectiveness analysis is used to assess the costs and outcomes of health care interventions in order to arrive at an overall valuation for those options.